Compumedics Limited

Compumedics Limited is an Australian medical technology company that focuses on the design, manufacture, and distribution of diagnostic equipment for sleep disorders and neurodiagnostic testing. Its core offerings include polysomnography systems used in laboratory settings, portable home sleep testing devices, and electroencephalography platforms for brain activity monitoring. These products are employed by clinicians to detect conditions such as obstructive sleep apnea, central sleep apnea, insomnia, narcolepsy, and various seizure disorders. The company also provides associated software solutions that enable data acquisition, analysis, reporting, and long‑term patient management. Compumedics serves a diverse customer base that encompasses hospitals, independent sleep clinics, neurology practices, research institutions, and occupational health providers. Its market reach extends beyond Australia to North America, Europe, and Asia through a combination of direct sales teams and authorized distributors. The firm’s products are intended to support both acute diagnostic evaluations and chronic disease management programs in adult and pediatric populations. By integrating hardware, software, and cloud‑based services, Compumedics aims to deliver end‑to‑end workflow solutions for sleep and neurodiagnostic care.

A distinguishing attribute of Compumedics is its specialization in integrated sleep and neurodiagnostic technologies that combine signal acquisition hardware with advanced analytics software. The company invests continuously in research and development to refine algorithms for sleep staging, respiratory event detection, and cerebral activity quantification. This focus enables its flagship product lines, such as the Somte PSG and Embla systems, to offer high‑resolution data capture combined with automated scoring capabilities. Regulatory compliance represents another core competency; Compumedics devices have obtained clearance from the U.S. Food and Drug Administration, bear CE marking for conformity with European medical device directives, and hold registrations with agencies such as Health Canada and the Therapeutic Goods Administration in Australia. These approvals allow the company to market its equipment as Class II medical devices in regulated jurisdictions, which underscores its commitment to safety and quality standards. Additionally, Compumedics maintains an ISO 13485 certified quality management system that governs its design, production, and post‑market surveillance activities. The combination of technical innovation, regulatory readiness, and global support infrastructure positions the firm as a niche player within the broader medical imaging and diagnostics sector.

Structurally, Compumedics Limited operates as an independent publicly listed company on the Australian Securities Exchange, trading under the ticker symbol CMP, with no parent entity disclosed in its public filings. The company maintains wholly owned subsidiaries in the United States and Europe that handle local sales, technical support, and regulatory affairs for those regions. These subsidiaries enable Compumedics to provide region‑specific customer service, conduct field trials, and adapt its products to meet local market requirements. In early March 2025, the organization disclosed a ransomware incident that affected its IT networks in both Australia and the United States, prompting an immediate containment response that included taking servers offline as a precautionary measure. An independent forensic investigation was launched to assess the scope of the breach, evaluate potential impacts on customer data, and guide the restoration of services, including the Nexus360 patient data and lab management platform. The incident was reported to the Australian Cyber Security Centre, and the company indicated that backed‑up data would facilitate recovery while work continued to bring affected systems back online.